DDInter1837 DDInter740
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Toremifene {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Toremifene {u} (Compound) downregulates {v} (Gene) SHB
SHB {u} (Gene) is downregulated by {v} (Compound) Flecainide
Toremifene {u} (Compound) causes {v} (Side Effect) Jaundice
Jaundice {u} (Side Effect) is caused by {v} (Compound) Flecainide
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Toremifene {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Toremifene {u} (Compound) downregulates {v} (Gene) SHB
SHB {u} (Gene) is regulated by {v} (Gene) CDK6
CDK6 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Toremifene {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Toremifene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Mefloquine
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Toremifene may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Toremifene (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Flecainide (Compound)
Toremifene (Compound) downregulates SHB (Gene) and SHB (Gene) is downregulated by Flecainide (Compound)
Toremifene (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Flecainide (Compound)
Toremifene may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Toremifene (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Toremifene (Compound) downregulates SHB (Gene) and SHB (Gene) is regulated by CDK6 (Gene) and CDK6 (Gene) is upregulated by Flecainide (Compound)
Toremifene (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Toremifene may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)